肺动脉高压模型 z-bo 2020-12-04 356

　　Objective: To explore the preventive and therapeutic effects of diamidine (DIZE) on pulmonary hypertension (PAH) model rats. Methods: Left lobectomy combined with monocrotaline (MCT) subcutaneous injection into the abdominal wall was used to establish a PAH rat model. 100 adult male Wistar rats were randomly divided into a blank control group (group A), a DIZE control group (group B), and a PAH model group (Group C), DIZE treatment PAH model group (D group) and (DIZE+C-16) treatment PAH model group (E group), using active fluorescence resonance energy transfer (FRET) and enzyme-linked immunosorbent assay (ELISA) methods Measure the levels of angiotensin-converting enzyme 2 (ACE2), serum IL-6 and IL-8, measure mean pulmonary artery pressure (mPAP), right ventricular hypertrophy index (RVHI), and calculate the ratio of media thickness to pulmonary artery outer diameter (WT ), intimal hyperplasia score, and analysis of pulmonary vascular disease by elastic fiber staining. Results: Comparison of RVHI, ACE2 enzyme activity, WT and intimal hyperplasia score: Compared with group A, the difference between group C, group D and group E was statistically significant (P<0.05); the difference between group D and group E was statistically significant (P<0.05). The five groups had statistically significant differences in the overall analysis of each index (P<0.05).

　　 Conclusion: Ermidine can increase the activity of ACE2 enzyme, and effectively reduce mPAP, RVHI and WT, and at the same time reduce pulmonary artery media hypertrophy and inhibit pulmonary arteriole intimal hyperplasia. The conclusions of this study provide an experimental basis for the treatment of human PAH with eramidine.